-
Our scientific team leverages innovative technologies to rapidly interrogate biomarker data so you can stratify patients, identify novel drug targets, characterize MoA, and swiftly reach actionable information.
- Translational informatics
- Biometrics
-
Full-service oncology trial solutions speed the journey from preclinical to first-in-man to post-market.
- Early phase oncology site network for predictable start-up and performance
- Highly experienced oncology-only trial team
- Accelerated pathway to proof of concept
- Patient stratification assays
- Translational bioinformatics and innovative data delivery
- Immune monitoring
-
Spend more time on research and less time searching for unique human donors.
- Healthy human PBMCs characterized for HLA Class I and II
- Demonstrated functionality
- Purified primary cells (such as monocytes, NK, and Tregulatory cells)
- Disease state PBMCs
- Leukopaks
-
Scientists, informaticists, and global logistics teams work in concert to collect, assay, and interpret highly complex biological data.
- Advanced custom cell-based and ligand-binding assays
- Global biorepositories and biobanking
- Comprehensive immune monitoring
- Bioanalytical services for large molecules
- Consistent global specimen collection and processing for accurate results
-
End-to-end expertise informs every point on the product pathway.
- Clinical trials for diagnostics and medical devices
- Regulatory strategy development and execution
- Market access and evidence strategies
- Regulatory and clinical utility study design
-
End-to-end solutions for developing treatments for rare diseases, from regulatory strategy and protocol design and conduct of global clinical trials to successful regulatory agency submissions.
- Specialized expertise in rare diseases and complex trials
- Complete regulatory support, including orphan drug applications
- Protocol development
- Biostatistics and database design for small patient populations
- Pioneering approaches to patient recruitment and engagement
- In-depth knowledge of FDA and EMA requirements
- Single resource for biomarkers linked to a disease
The new science of accelerating innovation
Omics + big data + biomarker-guided drug development. It’s a new reality, bringing unprecedented abilities to interrogate and translate biological information—and unprecedented opportunities for life sciences companies to achieve their goals faster and more cost-effectively. This fundamental shift requires a new approach to drug development. Precision for Medicine is leading the way.
Explore our services- Translational Informatics and Biometrics
- Oncology Solutions
- Biomaterials
- Specialty Lab Services
- Diagnostics and Medical Device Solutions
- Rare and Orphan Solutions
-
December 17, 2018
Precision Medicine Group Acquires Stern Investor Relations, Inc.
Read more... -
December 3, 2018
Clinical Omics - Unlocking the Value of Complex Biomarker Data
Discover more... -
October 16, 2018
Precision for Medicine Acquires Liquid Biopsy and Tissue Profiling Pioneer ApoCell
Get the story...
Precision for Medicine can help you find and extract the long-term value of innovative drugs
We develop your assays and manage global logistics, speeding to actionable answers. We use biomarkers to stratify patients, incomparably improving your R&D efficiency and success. We manage every aspect of your clinical trials from sites to biomarkers to diagnostics, all under a single roof. And we’re constantly adding services and expertise under that roof to support medical innovators — like our recent acquisition of ETHOS Health Communications, specializing in the interpretation and communication of medical science. In short: Precision dramatically accelerates your pathway from proof of concept to drug approval.
